Los inhibidores de PCSK9, de la innovación a la aplicación clínica sostenib / PCSK9 inhibitors: from innovation to sustainable clinical application
Rev. esp. cardiol. (Ed. impr.)
; 71(12): 996-998, dic. 2018.
Article
in Es
| IBECS
| ID: ibc-179004
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
No disponible
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Proprotein Convertase 9
/
Hyperlipoproteinemia Type II
/
Cholesterol, LDL
Limits:
Humans
Language:
Es
Journal:
Rev. esp. cardiol. (Ed. impr.)
Year:
2018
Document type:
Article